Analyst firms · Morgan Stanley · IMRX
Morgan Stanley IMRX price target and rating history
Immuneering Corporation (IMRX) · Health Care
Morgan Stanley rates Immuneering Corporation (IMRX) Underweight with a $14 price target, as of its latest action on Dec 13, 2024. It has published 4 rating actions on IMRX since August 2021, including 1 upgrade and 2 downgrades.
- Current rating
- Underweight
- Price target
- $14
- Median target, all firms
- Too few
- Actions on IMRX
- 4
Morgan Stanley price target on IMRX
Every Morgan Stanley rating on IMRX
- Dec 13, 2024
- Apr 19, 2023
- Feb 3, 2023
- Aug 24, 2021
How other firms rate IMRX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $14 | Aug 6, 2026 |
| Cantor Fitzgerald | Overweight | $17 | Jul 8, 2026 |
Questions about Morgan Stanley and IMRX
- What is Morgan Stanley's price target for IMRX?
- Morgan Stanley's latest stated price target for Immuneering Corporation (IMRX) is $14, from its action on Apr 19, 2023.
- What is Morgan Stanley's rating on IMRX?
- Morgan Stanley rates IMRX Underweight, a bearish rating, as of Dec 13, 2024.
- When did Morgan Stanley last change its view on IMRX?
- On Dec 13, 2024, Morgan Stanley downgrades to Underweight from Equal-Weight.
All Morgan Stanley ratingsIMRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.